Cardiotoxicity Risk of Cancer Treatment in Patients With Underlying Cardiomyopathies: Is Hypertrophic Cardiomyopathy Any Different?

Mayo Clin Proc. 2024 Feb;99(2):191-193. doi: 10.1016/j.mayocp.2023.12.013.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Cardiomyopathies* / chemically induced
  • Cardiomyopathies* / therapy
  • Cardiomyopathy, Hypertrophic* / complications
  • Cardiotoxicity / etiology
  • Humans
  • Neoplasms*
  • Patients